KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMY) Shares Repurchased (2017 - 2023)

Bristol Myers Squibb has reported Shares Repurchased over the past 12 years, most recently at $4.0 billion for Q3 2023.

  • Quarterly Shares Repurchased rose 470.61% to $4.0 billion in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $4.0 billion through Jun 2024, down 6.37% year-over-year, with the annual reading at $5.2 billion for FY2023, 35.57% down from the prior year.
  • Shares Repurchased was $4.0 billion for Q3 2023 at Bristol Myers Squibb, up from $905.0 million in the prior quarter.
  • Over five years, Shares Repurchased peaked at $7.0 billion in Q4 2019 and troughed at $81.0 million in Q1 2020.
  • The 5-year median for Shares Repurchased is $1.4 billion (2020), against an average of $2.0 billion.
  • Year-over-year, Shares Repurchased skyrocketed 2091.36% in 2021 and then plummeted 95.0% in 2023.
  • A 5-year view of Shares Repurchased shows it stood at $7.0 billion in 2019, then crashed by 79.07% to $1.5 billion in 2020, then soared by 87.78% to $2.8 billion in 2021, then dropped by 12.18% to $2.4 billion in 2022, then soared by 65.56% to $4.0 billion in 2023.
  • Per Business Quant, the three most recent readings for BMY's Shares Repurchased are $4.0 billion (Q3 2023), $905.0 million (Q2 2023), and $250.0 million (Q1 2023).